| Position | Action |
|---|---|
| Confirmed daily close above $89 on volume expansion | Add up to 33% of intended full size |
| Break below $81.40 | Stop-out |
| Asymmetric risks stacked but deferred (MACD compressing, declining 200 SMA overhead, unvalidated 72% EPS rebound) | Use smaller sizing (10-25%) if engaging before $89 confirmation |
MDT is a fundamentally improving business with accelerating revenue, expanding margins, and a deeply discounted forward valuation that is coiling for a breakout above $89, with catalysts and macro conditions supporting a long position.
| Indicator | Value | Signal |
|---|---|---|
| Close | $87.16 | neutral |
| 50 SMA | $81.40 | bullish |
| 200 SMA | $88.60 | bearish |
| 10 EMA | $85.78 | bullish |
| MACD | +1.49 | bullish |
| MACD Histogram | +0.11 | neutral |
| RSI | 62.16 | neutral |
| Bollinger Upper Band | $88.87 | bearish |
| Bollinger Middle Band | $84.23 | neutral |
| Bollinger Lower Band | $79.59 | bullish |
| ATR | 2.19 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
HOLD MDT: Maintain $82.75 trailing stop, add on confirmed $89 breakout; FY27 Q1 earnings is the binary resolution event
The HOLD consensus is correct. MDT's 13.59x forward P/E and 3.35% yield present an attractive asymmetric setup, but the 72% EPS rebound expectation (from $3.73 TTM to $6.41 forward) remains unvalidated ahead of the FY27 Q1 print. With MACD compressing 76%, the stock sitting $1.44 below the declining 200 SMA ($88.60), and sector volume risks signaled by ISRG procedure softness, probability of clean breakout below 70% argues against front-running. The $82.75 trailing stop provides risk discipline; the $89 confirmed close trigger provides clean re-engagement on earnings catalyst confirmation. Do not add at $87 levels given stacked asymmetric risks and deferred binary catalyst.
When: Break below $81.40
Then: Stop-out / close position
Net debt declining and balance sheet strengthening
↩ rebuts: “Refutes bear's melting ice cube narrative about goodwill-heavy balance sheet”
· concedes: Current HOLD rating is appropriate defensive posture for those without confirmation of breakout above $89; TTM P/E of 23.4x reflects fiscal year distorted by tax-related charges and restructuring items (market has moved past this); Forward PEG of 1.7 looks elevated but only because 'G' is compressed by depressed TTM EPS; Existing holders should HOLD with positive bias rather than buy aggressively until breakout confirmation
MDT is a HOLD-or-sell candidate, not a buy. The current setup is a rally at critical overhead resistance ($88.60 200 SMA) with decelerating momentum, fragile fundamentals (100% FCF payout ratio), and multiple underweighted headwinds (FX, GLP-1, procedure volume softness, tariff risk) that don't justify initiating new longs at $87.16.
· concedes: Fundamentals are genuinely improving — Q4 FY26 margin expansion of 280 bps and revenue trajectory are real; The 3.35% dividend yield is attractive for income-focused holders who are already long; CE Mark for VT ablation is a genuine regulatory positive, even if commercial impact is delayed; The Class II recall risk is manageable in isolation — it's the clustering risk that's the concern; If MDT breaks above $89 with volume expansion, the technical thesis changes and a pullback becomes a second entry opportunity
→ vs conservative: MACD histogram compression is normal deceleration in a maturing trend, not a sell signal; FCF payout concern ignores $9.22B liquidity cushion and 2.13 current ratio; 200 SMA is a $1.44 test, not a hard ceiling
→ vs neutral: Sector headwinds (GLP-1, ISRG) are already priced in at $87, not $106; new CE mark for VT ablation and CoreMap strategic investment are unpriced upside catalysts
Support: 79.59 · 81.4 · 84.23 · 85.78 | Resistance: 88.6 · 88.87 · 89
MDT is in a mid-stage recovery rally, up ~19% from the May 2026 low near $73 to $87.16. The stock trades above short and medium-term moving averages (10 EMA $85.78, 50 SMA $81.40) but remains below the critical 200-day SMA at $88.60. Momentum is positive but decelerating—MACD at +1.49 with histogram compressing from +0.46 to +0.11, RSI at 62.16 offering room to run. ATR elevated at 2.19 supports a trailing stop near $82.75. Recommendation: HOLD pending confirmed breakout above $89.
Market Cap
$111.57 Billion
P/E Ratio (TTM)
23.37
Forward P/E
13.59
PEG Ratio
1.7
Price to Book
2.26
EPS (TTM)
$3.73
Forward EPS
$6.41
Dividend Yield
3.35%
TTM Revenue
$36.36B
Gross Margin
65.3%
EBITDA
$10.10B
Net Income
$4.80B
Profit Margin
13.2%
Operating Margin
22.0%
Total Assets
$93.03B
Total Equity
$50.07B
Goodwill
$42.59B
Intangible Assets
$10.15B
Total Debt
$27.96B
Net Debt
$25.95B
Current Ratio
2.13
Working Capital
$13.13B
Debt to Equity
58.2%
Cash & Equivalents
$1.95B
Short-term Investments
$7.27B
TTM Free Cash Flow
$4.63B
Operating Cash Flow (Q4 FY26)
$2.573B
Capital Expenditures (Quarterly)
$450-500M
Annual Dividends Paid
$3.6B
Annual Share Buybacks
$1B+
ROE
9.84%
ROA
4.92%
Book Value per Share
$38.64
Tangible Book Value
-$3.27B
Beta
0.566
52-Week High
$106.33
52-Week Low
$73.31
50-Day Moving Average
$80.98
200-Day Moving Average
$90.06
Implied Current Price
~$87.17
Quarterly Revenue (Q4 FY26)
$9.807B
Quarterly Operating Income (Q4 FY26)
$2.013B
Quarterly Operating Margin (Q4 FY26)
20.5%
Quarterly Net Income (Q4 FY26)
$1.244B
Quarterly Diluted EPS (Q4 FY26)
$0.96
Strengths
Concerns
Medtronic presents a constructive fundamental setup with accelerating revenue growth, margin expansion, and attractive forward valuation trading at a forward P/E of 13.59. The company generates robust free cash flow ($4.63B TTM) sufficient to fund substantial capital returns ($4.6B+ annually in dividends and buybacks), supported by a healthy balance sheet with manageable leverage (Net Debt/EBITDA ~2.6x). However, the stock remains below its 200-day moving average, reflecting market hesitation despite the improving fundamentals. The aggressive earnings normalization expectation (TTM EPS $3.73 to forward $6.41) creates both opportunity and downside risk ahead of the next earnings report. Recommendation: HOLD with positive bias; income investors may BUY for the 3.35% dividend yield.